Literature DB >> 15735311

Residual risk of transfusion-transmitted viral infections in Spain, 1997-2002, and impact of nucleic acid testing.

M Alvarez do Barrio1, R González Díez, J M Hernández Sánchez, S Oyonarte Gómez.   

Abstract

Estimates of the risk of bloodborne viral infections are essential for monitoring the safety of the blood supply and the impact of new screening tests. Incidence rates of seroconversion and the residual risk for HBV, HIV and HCV were calculated among Spanish repeat donors between 1997 and 1999 at 22 blood donation centres, and at 7 centres between 2000 and 2002. The residual risk per million donations was estimated to be 18.67 for HBV, 2.49 for HIV and 10.96 for HCV (between 1997 and 1999). For the 2000-2002 period, the residual risk per million donations was estimated to be 9.78 for HBV, 2.48 for HIV and 3.94 for HCV. Between 1999 and 2003, about 3.4 million donations were tested by NAT, mainly in pools of 44 donations, in 12 of the 22 Spanish blood donation centres participating in the study. Eight anti-HCV negative and HCV-RNA positive donations were found, which represent an approximate yield of 1/420,000, versus a projected yield of 1/240,000 obtained from 1995-1997 data. The residual risks of transfusion-transmitted viral infections in Spain were low, and with the implementation of NAT these risks are even lower.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735311

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  9 in total

1.  Evolution of the residual risk of HBV, HCV and HIV transmission through blood transfusion in the Region of Valencia, Spain, during a 15-year period (2003-2017).

Authors:  Carlos López-Menchero; Manuel Alvarez; Pascual Fernández; María Guzmán; María I Ortiz-de-Salazar; Cristina Arbona
Journal:  Blood Transfus       Date:  2019-11       Impact factor: 3.443

Review 2.  New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.

Authors:  Mary C Kuhns; Michael P Busch
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

3.  Association of torque teno virus (TTV) and torque teno mini virus (TTMV) with liver disease among patients coinfected with human immunodeficiency virus and hepatitis C virus.

Authors:  M García-Álvarez; J Berenguer; E Alvarez; M Guzmán-Fulgencio; J Cosín; P Miralles; P Catalán; J C López; J Ma Rodríguez; D Micheloud; Ma A Muñoz-Fernández; S Resino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-09-16       Impact factor: 3.267

Review 4.  Therapeutic amenorrhea in patients at risk for thrombocytopenia.

Authors:  Meredith K Martin-Johnston; Olanma Y Okoji; Alicia Armstrong
Journal:  Obstet Gynecol Surv       Date:  2008-06       Impact factor: 2.347

5.  Reducing the risk of hepatitis B virus transfusion-transmitted infection.

Authors:  Christoph Niederhauser
Journal:  J Blood Med       Date:  2011-07-18

Review 6.  Epidemiology of Hepatitis B Virus Infection in China: Current Status and Challenges.

Authors:  Yong-Ping Yan; Hai-Xia Su; Zhao-Hua Ji; Zhong-Jun Shao; Zhong-Shu Pu
Journal:  J Clin Transl Hepatol       Date:  2014-03-15

7.  Epidemiology of hepatitis B virus infection: results from a community-based study of 0.15 million residents in South China.

Authors:  Fangfang Zeng; Pi Guo; Yun Huang; Wei Xin; Zhicheng Du; Shuming Zhu; Yu Deng; Dingmei Zhang; Yuantao Hao
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

Review 8.  Transfusion-transmitted infections.

Authors:  Florian Bihl; Damiano Castelli; Francesco Marincola; Roger Y Dodd; Christian Brander
Journal:  J Transl Med       Date:  2007-06-06       Impact factor: 5.531

9.  Comment on: One window-period donation in two years of individual donor-nucleic acid test screening for hepatitis B, hepatitis C and human immunodeficiency virus.

Authors:  Marion Vermeulen
Journal:  Rev Bras Hematol Hemoter       Date:  2013
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.